Guillain-Barre syndrome (GBS) associated with COVID-19 infection that resolved without treatment in a child

Samir Kanou,1 Lama Wardeh1,1, Sandhya Govindarajan,2 Kayleigh Macnay1

SUMMARY
A 9-year-old boy presented with unbalanced gait, back pain and lower limb weakness. His physical examination revealed almost absent lower limbs reflexes and cerebrospinal fluid (CSF) showed albuminocytologic dissociation. The brain and spine MRI with contrast illustrated abnormal enhancement—suggestive of Guillain-Barré syndrome. The case had limited distribution and it did not progress beyond the presenting clinical involvements. They did not need immunotherapy, self-recovered, managed conservatively using painkillers and gabapentin along with physiotherapy—with a wait and see approach. The child is now almost back to normal after 8–12 weeks.

BACKGROUND
COVID-19 disease is caused by SARS-CoV-2 virus infection. It has been seen symptomatically among many adults across the world. In children, the disease has been found to be more asymptomatic—with many not being aware they have even been infected.1 However, evidence is increasing that secondary neurological disorders caused by COVID-19 could affect both adults and children. The association between COVID-19 infection and Guillain-Barré syndrome (GBS) has been documented well in adult patients—with few cases only in paediatric patients.2

GBS is an acute immune-mediated polyradiculoneuropathy in nature that is often associated with a preceding illness (2–4 weeks earlier)—usually a respiratory tract or gastrointestinal tract infection. It usually manifests by ascending paralysis and collateral sensory impairment.3,4 The paralysis may reach the whole cerebrospinal route with bulbar respiratory centre involvement in some severe cases, which can put the patient at risk of having apnoea and paralytic respiratory failure.

Reported literature until present, shows eight paediatric patients who had GBS associated with COVID-19.3–14

All children required treatment with intravenous immunoglobulin with one child requiring plasma exchange,3,2,15 because they met this level of therapy criteria. Neither during admission nor for several weeks earlier, our patient did not show either the classic COVID-19 infection symptoms, like fever, cough, or taste or smell changes, or the PIMS-TS (Paediatric multisystem inflammatory syndrome Temporally associated with SARS-CoV-2) symptoms,16 and he had limited neurological involvement. He had reversible and self-resolving condition which didn’t require specific treatment.

CASE PRESENTATION
A 9-year-old boy presented due to worsening back pain and unsteadiness. He was accompanied by his mother who described ongoing back pain that had worsened over the last 3 weeks. This wasatraumatic with no clear cause. He had no history of blurred/double vision or any abnormal autonomic symptoms and there was no bowel or bladder incontinence. Over this time, she had noticed he became more unsteady on his feet going from a previously fit and active 9-year-old boy to now needing assistance with basic activities of daily living like walking and dressing. He had his legs feeling weak beneath him. He did not have any of the most common symptoms of COVID-19 infection including cough, fever, smell sense or taste loss. Other systems review was unremarkable and there was no clinical evidence of any single or multiorgan dysfunction.16 His mother stated she thought his appetite had decreased over this time alongside some mild weight loss.

His only medical history to note was low vitamin D levels, for which he was on cholecalciferol. There was no significant family history.

On examination, he was alert and orientated. Examination of the respiratory, cardiovascular and gastrointestinal system were unremarkable. On neurological examination his cranial nerves were intact, he had no sensory or fasciculations, with normal sensations (touch, pain, temperature, proprioception and pressure). He was objectively nervous about walking. He was able to walk 10 m across an open space with help (grade 3 on GBS disability scale).17 He was unable to run or walk on his tip toes and could not jump with 2 ft. Based on his history and examination, he was admitted to the children’s ward and investigations were undertaken.

INVESTIGATIONS

Blood results

- Haemoglobin 126 g/L (normal range 111–147 g/L), white cell count 5.9×10^9/L (normal range 4.5–14.5×10^9/L), slightly decreased neutrophils 1.2×10^9/L (normal range 1.5–8×10^9/L), platelets 414×10^9/L (normal range 150–450×10^9/L).
- C reactive protein 2.4 mg/L. (Normal range ≤5.0 mg/L).
- Erythrocyte sedimentation rate 10 mm/hour slightly elevated (normal range 1–7 mm/hour).
Case report

Brain and spine MRI with contrast showed symmetrical enhancement of the proximal mastoid segments of the facial nerves (Figure 1) and the cauda equina (Figure 2).

Differential diagnosis
Since the clinical presentation was mainly of back pain and lower limbs weakness which affected the patient’s ability to stand and walk steadily, we investigated all other possibly underlying orthopaedic, muscular and neurological causes including other autoimmune and/or axonal damage to peripheral nerves or roots. A significant degree of areflexia in both legs and the albuminocytological dissociation in the cerebrospinal fluid (CSF) on top of a special enhancement around some lower legs supplying nerves routes on the MRI were all suggestive of GBS.

Treatment
We managed the patient at the local district general with specialist paediatric neurology input from the local tertiary centre. As per our local guidelines and the paediatric neurology consultation, this patient disability grade was static (2–3) and did not worsen during admission. Conversely, he clinically improved gradually during hospital stay, hence intravenous immunoglobulin was not given.

He was managed conservatively, monitoring active symptoms as well as peak flow to ensure no respiratory involvement. His peak flows remained normal throughout admission (ranging from 210 to 240).

He had ongoing back and leg pain, for which he was successfully treated for using analgesics along with an increasing dose of gabapentin 10 mg/kg once a day on day 1, 10 mg/kg two times per day a day on day 2, 10 mg/kg three times per day on day 3 and then stopped.

He obtained regular physiotherapy in order to regain skills and to avoid any muscle wasting.

Outcome and follow-up
The patient has been recovering gradually without the use of any intravenous immunoglobulin or plasmapheresis and was discharged home to continue therapy in the community. He was seen in an outpatient clinic to assess his condition a few months postdischarge. Here he was found to have improved significantly. Normal power noted during the follow-up with good reflexes recovery. Now, he is able to walk independently. However, he still is not yet back to baseline—becoming tired more easily than usual with mild manageable backpain. He will continue to be followed up in clinic for the next year.

Discussion
GBS is an immune-mediated polyradiculoneuropathy.

Symptoms usually appear 2–4 weeks after a viral infection. However, no definite resources can confirm this period after COVID-19 infection, taking into consideration that COVID-19 PCR may remain positive for several weeks. Therefore, our patient may have been asymptomatically infected weeks before showing GBS symptoms.

Affected patients can present with limb or cranial-nerves weakness, loss of deep tendon reflexes, sensory and dysautonomic symptoms.

The main pathophysiology for the clinical presentation is demyelination and/or axonal damage to peripheral nerves or roots.
Other causes of muscle weakness and unsteady gait (transverse myelitis, myositis, etc) must be ruled out by a precise neurological examination along with several laboratory investigations and targeted imaging.

Neurological symptoms in COVID-19 presents as either life-threatening conditions such as GBS, encephalitis, encephalopathy, meningitis and cerebrovascular accidents, or as long-term symptoms such as chronic fatigue and myalgia termed as Long COVID-19 or Post-acute sequelae of COVID-19. The association of COVID-19 with GBS has been reported with incidence being more common in adult population with symptoms ranging from being mild to severe needing mechanical ventilation and mortality. A review of published case reports suggests that GBS presented as cranial nerve involvement in the absence of muscle weakness in 22.9% patients: as classic sensory motor variant in 73% patients and pure motor variant in 2.1% patients. The electrodiagnostic pattern was considered demyelinating in 82.4% of the generalised variants.

**Patient’s perspective**

My son has always been very active, one of the fastest running in class and the best player in his team. From the time he started to refuse to play outside and avoid chasing his baby brother and saying his legs feel different we knew something was wrong but never thought it was going to be that serious. The day when we got to the hospital my whole world collapsed, he couldn’t stand, and he was in a significant amount of pain his muscles were that weak that he even had a fall when sat on the toilet. It was surreal and scary. The Hospital paediatric team were fantastic, and I pray for them every day. The doctors involved me and my husband in every plan and they have listened to us, they put things at easy and done everything they could in time to save my son’s life even when things are not anywhere near with COVID-19. It took a lot of exams to finally get to GBS. Treatment options were discussed, and they were very honest in telling us that my son’s condition was very rare, and more research needs to be done but they assured me that he was going to overcome this. We had lots of prayers from family, colleagues, friends and that faith in God and love around us made this miracle happen. We have returned to work after 3 months caring for him and he has returned to school that faith in God and love around us made this miracle happen.

**Learning points**

- Guillain-Barré syndrome (GBS) is one of the neurological manifestations in COVID-19.
- The symptoms can vary from being mild to very severe including needing mechanical ventilation and death.
- Management depends on clinical severity of the disease ranging from conservative therapy to immune-mediated therapy.
- Since it is a newly reported association further studies are needed to establish the pathophysiology of GBS and COVID-19.

Another systematic review suggests that GBS associated with COVID-19 responded to intravenous immunoglobulins (Ig) in 78% of patients.

**REFERENCES**


